Information Journal Paper
APA:
Copy. (2020). Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. medRxiv, -(-), 0-0. SID. https://sid.ir/paper/680854/en
Vancouver:
Copy. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. medRxiv[Internet]. 2020;-(-):0-0. Available from: https://sid.ir/paper/680854/en
IEEE:
Copy, “Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report,” medRxiv, vol. -, no. -, pp. 0–0, 2020, [Online]. Available: https://sid.ir/paper/680854/en